News

2017.08.01News Release

Maruho Succeeds Manufacturing and Marketing Approval for Acne Vulgaris Treatment "Epiduo^® Gel"

2017.07.11News Release

Maruho Launches Topical Scalp Psoriasis Treatment "Comclo^® Shampoo 0.05%" in Japan

2017.07.07News Release

Maruho Succeeds Marketing Approval for Anti-Atopic Dermatitis Agent "Protopic^® Ointment" in Japan

2017.07.03News Release

Maruho receives manufacturing and marketing approval for Anti-Herpes Virus Agent "Amenalief^® Tab. 200mg" in Japan

2017.06.05News Release

Maruho and the Japanese Dermatological Association announce the Joint Operation of the Maruho Prize

2017.03.30News Release

Maruho receives manufacturing and marketing approval in Japan for Topical Scalp Psoriasis Treatment "Comclo^® Shampoo 0.05%"

2017.03.14News Release

Toray and Maruho Enter License Agreement for RORγt Inhibitor

2017.03.06News Release

Cutanea (Maruho's US Subsidiary) Unveils Aktipak™ (erythromycin and benzoyl peroxide) Gel, 3%/5%, Convenient Acne Treatment for "On-the-Go" Patients

2016.12.09News Release

The "Galderma Award" Transfers to Maruho

2016.11.04News Release

Maruho Launches Acne Vulgaris Treatment "Epiduo^® Gel" in Japan

2016.09.28News Release

Maruho and Astellas Enter License Agreement for the Development and Commercialization of a Topical Formulation of JAK Inhibitor peficitinib (ASP015K) for Treatment in the Skin Disease Area

2016.09.28News Release

Chugai and Maruho Announce License Agreement of Nemolizumab (CIM331), a Novel Biologic in the Skin Disease Area for the Japanese Market

2016.09.21News Release

Maruho enters a License Agreement with Dermira for Hyperhidrosis treatment agent DRM04

2016.09.16News Release

Maruho launches infantile hemangioma treatment"Hemangiol^® Syrup for Pediatric 0.375%" under a license from Pierre Fabre Laboratories

2016.07.20News Release

Maruho and Galderma Strengthen Strategic Alliance in Japan

2016.07.04News Release

Maruho receives manufacturing and marketing approval in Japan for infantile hemangioma treatment "Hemangiol^® Syrup for Pediatric 0.375%" under a license from Pierre Fabre Laboratories